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Abstract  The  association  between  heart  disease  and  pregnancy  is  increasingly  prevalent.
Although  most  women  with  heart  disease  tolerate  the  physiological  changes  of  pregnancy,  there
are heart  conditions  that  manifest  for  the  ﬁrst  time  during  pregnancy  and  others  that  totally
contraindicate  a  pregnancy.  It  is  therefore  important  to  establish  multidisciplinary  teams  dedi-
cated to  the  management  of  women  with  heart  disease  who  intend  to  become,  or  who  already
are, pregnant.  The  aim  of  this  article  is  to  systematically  review  current  knowledge  on  the
approach to  women  with  high-risk  cardiovascular  disease  during  pregnancy.
Published  by  Elsevier  Espan˜a,  S.L.U.  on  behalf  of  Sociedade  Portuguesa  de  Cardiologia.  This  is
an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
PALAVRAS-CHAVE
Gravidez;
Cardiopatia;
Insuﬁciência  cardíaca
Cardiopatia  e  gravidez  --  o  estado  da  arte
Resumo  A  associac¸ão  entre  cardiopatia  e  gravidez  é  cada  vez  mais  frequente.  Ainda  que
a grande  maioria  das  mulheres  com  doenc¸as  cardíacas  tolere  as  alterac¸ões  ﬁsiológicas  da
gravidez,  existem  patologias  cardíacas  que  se  manifestam  pela  primeira  vez  durante  o  estado
gravídico e  outras  que  contraindicam  totalmente  uma  gravidez  pelo  risco  materno  que  lhe  está
associado.  Desta  forma,  torna-se  premente  a  criac¸ão  de  equipas  multidisciplinares  dedicadas  à
abordagem  de  mulheres  com  doenc¸a  cardíaca  que  pretendem  engravidar  ou  que  já  estão  grávi-
das. O  objetivo  deste  artigo  é  sistematizar,  com  base  no  conhecimento  atual,  a  abordagem  de
mulheres com  doenc¸a  cardiovascular  de  alto  risco  durante  a  gravidez.
Publicado  por  Elsevier  Espan˜a,  S.L.U.  em  nome  de  Sociedade  Portuguesa  de  Cardiologia.  Este e´
um artigo  Open  Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/licenses/
by-nc-nd/4.0/). Please cite this article as: Guimarães T, Magalhães A, Veiga A, et 
2019;38:373--383.
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ntroduction
he  spectrum  and  prevalence  of  heart  disease  in  preg-
ancy  varies  considerably  between  countries.  According  to
he  most  recent  information,  1-4%  of  all  pregnancies  in
ndustrialized  countries  are  complicated  by  cardiovascu-
ar  disease  (CVD).1 This  incidence  has  increased,  due  to
omen  becoming  pregnant  at  older  ages,  the  higher  preva-
ence  of  cardiovascular  risk  factors  (smoking,  diabetes,
besity  and  hypertension)  in  women  of  child-bearing  age,
nd  the  growing  number  of  women  with  corrected  congenital
eart  disease  (CHD)  who  reach  adulthood.  In  a  study  which
ncluded  13  Canadian  cardiology  centers,  CHD  accounted  for
0%  of  all  heart  disease  in  pregnancy,2 while  in  a  registry  at
he  Heart  Institute  of  the  University  of  São  Paulo,  Brazil,  that
ncluded  1000  pregnant  women  with  heart  disease  followed
or  10  years,  the  most  common  etiology  was  rheumatic  heart
isease,  found  in  55%  of  cases.3
Cardiomyopathies  are  rare  in  pregnancy,  although  they
re  an  important  cause  of  complications,  peripartum  car-
iomyopathy  (PPCM)  being  responsible  for  the  most  serious
dverse  events.4
Studies  suggest  that  pregnancy-related  mortality  has
ncreased  in  recent  decades,  with  a  growing  number  of
eaths  attributable  to  CVD,5 which  is  currently  the  leading
ause  of  maternal  death  in  Western  countries.6
emodynamic  adaptations  to  pregnancy
mportant  adaptations  to  the  cardiovascular  system  occur
n  response  to  pregnancy  to  meet  the  increasing  metabolic
eeds  of  both  mother  and  fetus  (Table  1).  Non-adaptive
emodynamic  changes  can  lead  to  maternal  and  fetal
orbidity.7 Failure  of  normal  adaptations  can  lead  to  decom-
ensation  of  existing  heart  disease,  the  onset  of  symptoms,
r  the  ﬁrst  manifestations  of  previously  unknown  disease,
nd  hence  pregnancy  is  often  considered  a  natural  stress
est.
Blood  volume  increases  considerably  during  pregnancy,
apidly  between  six  and  20  weeks,  and  less  markedly
etween  20  weeks  and  term,  with  a  mean  overall  increase
f  around  50%.8 Increased  erythropoietin  production  sti-
ulates  erythropoiesis,  which  can  rise  by  over  40%  in  a
regnant  woman  without  nutritional  deﬁciencies.9 However,
he  increase  in  plasma  volume  is  greater  than  that  of  red
lood  cell  mass,  resulting  in  hemodilution,  which  leads  to
hysiological  anemia  of  pregnancy.  Hemoglobin  levels  as  low
s  11  g/dl  are  considered  physiological.7 Cardiac  output  (CO)
ises  by  around  50%,  initially  due  mainly  to  increased  systolic
olume  and  then  to  increased  heart  rate  (HR)  in  the  third
rimester.  Peripheral  vascular  resistance  (PVR)  falls  during
regnancy,  leading  to  reductions  in  systolic  and  diastolic
lood  pressure  (BP).  BP  is  lowest  during  the  second  trimester
5-10  mmHg  below  initial  levels),  although  the  steepest  BP
alls  occur  between  six  and  eight  weeks  of  pregnancy.10 As
regnancy-related  changes  in  BP  occur  very  early,  BP  lev-
ls  later  in  the  pregnancy  should  be  compared  with  those
efore  pregnancy,  rather  than  with  those  recorded  in  the
rst  weeks.7 During  the  third  trimester,  BP  returns  to  pre-
onception  levels.
f
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CO  reaches  a peak  in  labor  and  immediately  after  deliv-
ry,  with  an  increase  of  60-80%.  This  is  due  to  various  factors,
articularly  higher  HR,  increased  preload  associated  with
terine  contractions  (for  each  uterine  contraction  300-500
l  of  blood  enters  the  systemic  circulation),  and  elevation
f  circulating  catecholamines.11 It  is  extremely  important
o  maintain  blood  volume  at  this  stage  and  care  should  be
aken  to  avoid  excessive  blood  loss,  which  could  drastically
educe  preload.  This  is  the  stage  at  which  there  is  greatest
isk  of  decompensation  of  heart  disease.
iagnosis  of  cardiovascular  disease  in  pregnancy
 complete  medical  history  is  essential,  focusing  on  char-
cterization  of  the  symptoms  and  signs  associated  with
he  physiological  changes  of  pregnancy.  Healthy  pregnant
omen  may  present  exertional  dyspnea,  fatigue  and  pal-
itations.  On  physical  examination,  lower  limb  edema  and
ugular  venous  distension  are  common  ﬁndings.  On  car-
iac  auscultation,  after  the  ﬁrst  trimester  the  ﬁrst  sound
s  louder,  and  a  ejection  systolic  ﬂow  murmur,  a  third  sound
nd  an  atrioventricular  diastolic  ﬂow  murmur  are  heard  in
0%,  80%  and  20%  of  cases,  respectively.7 However,  chest
ain,  new-onset  dyspnea,  symptomatic  hypotension,  unex-
lained  tachycardia,  palpitations  associated  with  syncope,
nd  cyanosis  should  be  always  considered  warning  signs.  Dif-
erential  diagnosis  should  be  based  on  a  detailed  clinical
istory,  with  additional  examinations  being  ordered  accord-
ng  to  clinical  suspicion,  weighing  their  risk  and  beneﬁt  and
nterpreting  the  results  in  the  clinical  context,  as  shown  in
able  2.12
The  negative  predictive  value  of  natriuretic  peptides  is
aintained  during  pregnancy,  and  they  have  been  shown  to
elp  exclude  heart  disease  in  pregnant  women.  However,
hanges  in  B-type  natriuretic  peptide  levels  in  pregnancy,
nd  their  prognostic  impact  in  pregnant  women  with  heart
isease,  remain  the  subject  of  debate.13
The  majority  of  pregnant  women  have  a  normal  electro-
ardiogram  (ECG),  but  elevation  of  the  diaphragm  by  the
regnant  uterus  can  lead  to  left  axis  deviation  of  15-20◦.
ther  possible  non-pathological  electrocardiographic  ﬁnd-
ngs  are  transient  ST-segment  and  T-wave  changes,  presence
f  a  Q  wave  and  inverted  T  waves  in  DIII,  an  attenuated  Q
ave  in  aVF,  and  inverted  T  waves  in  V1,  V2  and,  occasion-
lly,  V3.14
Transthoracic  echocardiography  (TTE)  is  the  gold
tandard  for  assessing  cardiac  function  during  pregnancy.
on-pathological  ﬁndings  in  a  pregnant  woman  include
ild  dilatation  of  all  four  chambers  (which  may  be  more
arked  in  the  right  atrium  and  ventricle),  transient  trivial
itral  regurgitation  (MR),  physiological  pulmonary  and  tri-
uspid  regurgitation  (TR),7 and  increases  in  CO  and  left  and
ight  ventricular  mass.15 Aortic  regurgitation  (AR)  is  always
athological.16 Transesophageal  echocardiography  can  be
seful  for  the  characterization  of  CHD  and  when  aortic
issection  or  prosthetic  valve  dysfunction  are  suspected,
articularly  for  diagnosing  vegetations  and  thrombi.If  examinations  involving  ionizing  radiation  are  called
or,  this  decision  requires  careful  consideration,  because
ven  though  the  priority  is  the  mother’s  health,  the  effects
n  the  fetus  must  also  be  taken  into  account.  The  radiation
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Table  1  Physiological  changes  in  pregnancy  (adapted  from  Sanghavi  et  al.7).
Pregnancy  Labor
1st  trimester  2nd  trimester  3rd  trimester
Hemodynamic CO  ↑  ↑↑  ↑↑  ↑↑↑↑
PVR ↓  ↓↓  ↓↓
HR ↑  ↑↑  ↑↑↑  ↑↑↑↑
BP ↑  ↑  ↔  (pain)
Neurohormonal  ↑  Sympathetic  activity
↑  Estrogen/progesterone/relaxin
RAAS  Plasma  volume  ↑↑  ↑↑↑  ↑↑↑↑  ↑↑↑↑↑
RBC mass  ↑  ↑↑  ↑↑  (autotransfusion)
Structural
changes
LV mass  ↑  ↑  ↑
Cardiac chamber
size
↑  Atria  and  ventricles
Aorta  ↑  Distensibility
↑: increased; ↓: decreased; ↔:  no change; BP: blood pressure; CO: cardiac output; HR: heart rate; LV: left ventricular; PVR: peripheral
vascular resistance; RAAS: renin-angiotensin-aldosterone system; RBC; red blood cell.
Table  2  Peripartal  acute  dyspnea:  differential  diagnosis  of  acute  peripartum  cardiomyopathy  (adapted  from  Bauersachs
et al.1,2).
Peripartum  car-
diomyopathy
Pre-existing  heart
disease
Pregnancy-
associated
myocardial
infarction
Pulmonary
and/or
amniotic
embolism
Myocarditis
History  More  frequent
after  delivery
More  frequent  in
the  2nd  trimester
Retrosternal  chest
pain,  abdominal
discomfort,
nausea
Pleuritic  chest
pain
Infection
Biomarkers  Elevated  NPs  Elevated  NPs  Elevated  troponin  Elevated
D-dimers,
troponin,  NPs
Elevated  troponin,
possibly  elevated
NPs
Echocardiography  LV  and/or  RV
dysfunction
Evidence  of
pre-existing
structural  valve
disease  or
congenital  defect
Regional  akine-
sis/hypokinesis
RV  dysfunction
and  elevated
pressure;
McConnell’s
sign
Regional  or
general
hypokinesis
Additional  tests  Consider  MRI  Consider  MRI
and/or  genetic
testing
Coronary
angiography
CT  or  V/Q
scan;  consider
angiography
MRI
Consider
myocardial  biopsy
onan
p).
d
d
b
C
s
c
a
n
uCT: computed tomography; LV: left ventricular; MRI: magnetic res
ventilation/perfusion.
dose  to  which  the  fetus,  which  is  protected  by  the  uterus,
is  exposed  tends  to  be  lower  than  that  received  by  the
mother,  although  the  fetus  is  more  sensitive.  The  effects
depend  on  the  radiation  dose  and  on  gestational  age;  if
possible  the  exam  should  be  postponed  until  after  the
ﬁrst  12  weeks  of  pregnancy,  the  period  of  major  organo-
genesis.  There  is  no  evidence  that  doses  of  <50  mGy  are
associated  with  increased  risk  of  miscarriage,  congeni-
tal  malformation,  growth  restriction  or  mental  problems
(https://emergency.cdc.gov/radiation/prenatalphysician.as
The  dose  to  which  a  fetus  is  exposed  from  a  chest  X-ray  is
<0.01  mGy,  but  even  so,  an  X-ray  should  only  be  performed
if  no  other  examination  can  clarify  the  etiology  of  the
mother’s  symptoms.  Computed  tomography  is  rarely  used  for
a
e
r
ice imaging; NPs: natriuretic peptides; RV: right ventricular; V/Q:
iagnosis  of  CVD  in  pregnancy  and,  given  the  high  radiation
oses  required,  is  not  recommended.  An  exception  can
e  made  if  the  mother’s  survival  is  at  stake  (Table  2).
ardiac  magnetic  resonance  imaging  (MRI)  appears  to  be
afe  for  both  mother  and  fetus17 and  can  be  useful  for
haracterizing  complex  heart  disease  and  disease  of  the
orta.  The  risk  to  the  fetus  from  exposure  to  gadolinium  is
ot  known  and  gadolinium  contrast  should  therefore  not  be
sed.14
Stress  testing,  either  exercise  or  pharmacological,  should
lso  be  avoided  in  pregnancy  due  to  the  risk  of  hypox-
mia,  fetal  bradycardia  and  even  fetal  loss,  caused  by
educed  placental  blood  ﬂow.  Pre-conception  stress  test-
ng  plays  an  important  role  in  assessing  functional  capacity,
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hronotropic  and  blood  pressure  response  to  exertion,  and
xertion-induced  arrhythmias  in  the  monitoring  of  patients
ith  CHD  and  asymptomatic  valve  disease.14 Stress  echocar-
iography  can  be  useful  for  pre-conception  assessment  of
yocardial  contractile  reserve  in  women  with  previous  PPCM
nd  recovery  of  left  ventricular  ejection  fraction  (LVEF),
ther  cardiomyopathies  with  slightly  impaired  LVEF,  valve
isease,  and  CHD.
isk  stratiﬁcation  of  pregnant  women  with
ardiovascular  disease
ssessment  of  the  risk  of  pregnancy  in  women  with  known
VD  should  be  individualized  and  ideally  performed  before
regnancy,  including  adjustments  to  medication  such  as  sus-
ending  contraindicated  drugs  and  introducing  alternatives.
everal  scores  have  been  created  to  stratify  the  risk  of
ardiovascular  complications  in  pregnancy,  the  most  com-
only  used  of  which  is  the  Cardiac  Disease  in  Pregnancy
CARPREG)  risk  score.18 The  European  Society  of  Cardiology
ESC)  guidelines  recommend  assessment  of  the  risk  of  car-
iovascular  complications  based  on  the  classiﬁcation  of  the
orld  Health  Organization  (WHO),  as  this  includes  predic-
ors  that  are  not  incorporated  in  the  CARPREG  and  other
isk  scores  (Tables  3  and  4).14
ype  of  delivery  in  cardiovascular  disease
he  type  of  delivery  should  be  decided  and  scheduled  by  a
ultidisciplinary  team.  The  preferred  mode  of  delivery  is
aginal,  with  a  delivery  plan  individualized  to  the  patient,
er  disease,  and  her  hemodynamic  proﬁle.  Cesarean  sec-
ion,  although  controversial,  is  indicated  for  patients  with
onditions  in  WHO  risk  group  IV,  under  oral  anticoagula-
ion  in  pre-term  labor,  with  decompensated  heart  failure
HF),  or  for  obstetric  indications.14 Tocolytic  beta-agonists
hould  not  be  used  in  mitral  stenosis  (MS)  since  by  inducing
Table  3  Modiﬁed  World  Health  Organization  classiﬁcation
of maternal  cardiovascular  risk:  principles  (adapted  from
Regitz-Zagrosek  et  al.14).
Risk
class
Risk  of  pregnancy  by  medical  condition
I  No  detectable  increased  risk  of  maternal
mortality  and  no/mild  increase  in  morbidity.
II Small  increased  risk  of  maternal  mortality  or
moderate  increase  in  morbidity.
III Signiﬁcantly  increased  risk  of  maternal  mortality
or severe  morbidity.  Expert  counseling  required.  If
pregnancy  is  decided  upon,  intensive  specialist
cardiac  and  obstetric  monitoring  is  needed
throughout  pregnancy,  childbirth  and  the
puerperium.
IV Extremely  high  risk  of  maternal  mortality  or
severe  morbidity;  pregnancy  contraindicated.  If
pregnancy  occurs  termination  should  be
discussed.  If  pregnancy  continues,  care  as  for
class  III.
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achycardia,  they  reduce  left  ventricular  (LV)  ﬁlling  time
nd  consequently  increase  left  atrial  pressure.  Alternatively,
tosiban,  an  oxytocin  antagonist,  can  be  used.  Corticoste-
oids  are  contraindicated  in  patients  with  decompensated
eart  disease  due  to  the  risk  of  pulmonary  congestion,  pul-
onary  edema  (PE)  and  cardiogenic  shock.
nfective  endocarditis
he  ESC19 and  the  American  College  of  Cardiology/American
eart  Association  (ACC/AHA)20 do  not  recommend  antibiotic
rophylaxis  during  vaginal  or  cesarean  delivery.  However,
n  the  Brazilian  Society  of  Cardiology  guidelines  prophy-
axis  against  infective  endocarditis  is  indicated  in  high-risk
atients,  with  2  g  ampicillin  associated  with  1.5  mg/kg  gen-
amicin  one  hour  before  birth.  In  allergic  patients,  penicillin
hould  be  replaced  by  1  g  vancomycin.21
alvular  heart  disease
tenotic  and  left-sided  valve  lesions  are  at  higher  risk  of
ecompensation  in  pregnancy  than  regurgitant  and  right-
ided  lesions.  Valve  stenosis  restricts  increases  in  CO,
aising  transvalvular  gradients  and  pressures  upstream  of
he  lesion,  and  is  therefore  less  well  tolerated  in  pregnancy
han  regurgitation,  since  regurgitant  volume  diminishes  with
ystemic  vasodilation  and  consequent  reduced  afterload.
echanical  heart  valves  are  associated  with  speciﬁc  prob-
ems  (see  below).
Although  most  women  with  less  severe  valve  disease  tol-
rate  pregnancy  well,  some  valve  lesions  are  considered
rohibitive:  severe  MS,  severe  symptomatic  aortic  stenosis
AS),  and  any  valve  disease  associated  with  LV  dysfunction
LVD)  and/or  pulmonary  hypertension  (PH).  Women  with
hese  conditions  should  receive  pre-conception  counsel-
ng  and  should  be  treated  before  pregnancy.  Hemodynamic
hanges  in  pregnancy  can  lead  to  increased  mitral  and  aor-
ic  valve  gradients  on  TTE,  leading  to  overestimation  of  the
everity  of  the  valve  lesion,22 and  so  stenosis  should  be  quan-
iﬁed  by  valve  area  assessed  using  planimetry,  or  by  pressure
alf-time  for  MS  or  by  the  continuity  equation  for  AS.23,24 For
omen  who  remain  stable  during  pregnancy,  term  delivery  is
ecommended.  Vaginal  delivery  with  good  pain  management
s  the  preferred  method  for  most  women  with  valve  disease.
ome  experts  suggest  a  cesarean  section  for  patients  with
evere  AS.14
itral  stenosis
S  is  the  most  common  valve  disease  in  women  of  child-
earing  age,  and  in  90%  of  cases  is  of  rheumatic  etiology.  The
emodynamic  changes  associated  with  pregnancy  (higher
R,  CO,  plasma  volume  and  red  blood  cell  mass)  lead  to
ncreased  left  atrial  pressure  and  PE.  Many  patients  with  MS
ecome  symptomatic  for  the  ﬁrst  time  during  pregnancy.
he  most  common  complications  are  reduced  functional
apacity,  arrhythmias  (most  often  atrial  ﬁbrillation  [AF])  and
E.  These  are  related  to  mitral  valve  area  and  NYHA  class24
nd  occur  more  often  in  the  second  and  third  trimesters,
hen  hemodynamic  changes  are  more  marked.25 If
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Table  4  Modiﬁed  World  Health  Organization  classiﬁcation  of  maternal  cardiovascular  risk:  application  (adapted  from  Regitz-
Zagrosek et  al.14).
Conditions  in  which  pregnancy  risk  is  WHO  I
Uncomplicated,  small  or  mild:
pulmonary  stenosis
patent  ductus  arteriosus
mitral  valve  prolapse
Successfully  repaired  simple  lesions  (atrial  or  ventricular  septal  defect,  patent  ductus  arteriosus,  anomalous  pulmonary
venous drainage)
Atrial  or  ventricular  ectopic  beats,  isolated
Conditions  in  which  pregnancy  risk  is  WHO  II  or  III
WHO  II  (if  otherwise  well  and  uncomplicated)
Unoperated  atrial  or  ventricular  septal  defect
Repaired  tetralogy  of  Fallot
Most  arrhythmias
WHO  II-III  (depending  on  individual)
Mild left  ventricular  impairment
Hypertrophic  cardiomyopathy
Native  or  tissue  valve  heart  disease  not  considered  WHO  I or  IV
Marfan  syndrome  without  aortic  dilatation
Aorta  <45  mm  in  aortic  disease  associated  with  bicuspid  aortic  valve
Repaired  coarctation
WHO  III
Mechanical  valve
Systemic  right  ventricle
Fontan  circulation
Cyanotic  heart  disease  (unrepaired)
Other  complex  congenital  heart  disease
Aortic  dilatation  of  40-45  mm  in  Marfan  syndrome
Aortic  dilatation  of  45-50  mm  in  aortic  disease  associated  with  bicuspid  aortic  valve
Conditions  in  which  pregnancy  risk  is  WHO  IV  (pregnancy  contraindicated)
Pulmonary  arterial  hypertension  of  any  cause
Severe  systemic  ventricular  dysfunction  (LVEF  <30%,  NYHA  III-IV)
Previous  peripartum  cardiomyopathy  with  any  residual  impairment  of  left  ventricular  function
Severe mitral  stenosis,  severe  symptomatic  aortic  stenosis
Marfan  syndrome  with  aorta  dilated  >45  mm
Aortic dilatation  of  >50  mm  in  aortic  disease  associated  with  bicuspid  aortic  valve
Native severe  coarctation
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symptoms  occur,  the  patient  should  be  started  on  beta-
blockers,  to  prolong  ventricular  ﬁlling  time  and  reduce  left
atrial  pressure,  and,  if  necessary,  diuretics  to  relieve  conges-
tion.  Anticoagulation  is  indicated  in  the  presence  of  AF,
atrial  thrombi  or  a  history  of  thromboembolism.  Percuta-
neous  mitral  commissurotomy  should  be  considered  only
when,  despite  medical  treatment,  the  patient  remains  in
NYHA  class  III/IV,  and  preferably  not  until  after  20  weeks
gestation.  Cardiac  surgery  should  be  reserved  for  life-
threatening  situations  in  which  all  other  measures  have
failed.14
Mitral  regurgitationThe  most  common  causes  of  MR  in  pregnant  women  are
rheumatic  valve  disease,  MVP  and  CHD.  Reduced  PVR  and  BP
during  pregnancy  explain  why  women  with  mild,  moderate
p
b
a
rciation functional class; WHO: World Health Organization risk
r  even  severe  MR  but  without  LV  dilatation  or  dysfunction
olerate  pregnancy  well.  However,  increased  plasma  volume
nd  CO  can  lead  to  HF  or  arrhythmias,  particularly  in  cases  of
evere  MR  and  in  patients  with  LV  dilatation  or  dysfunction.22
ortic  stenosis
icuspid  aortic  valve  is  the  main  cause  of  AS  in  women  of
hild-bearing  age,  and  is  frequently  associated  with  aortic
ilatation  and  coarctation,  which  further  increases  the  risk
n  pregnancy.  Mild  to  moderate  AS  is  generally  well  toler-
ted,  unlike  severe  AS,  which  is  associated  with  angina,
achyarrhythmias  and  PE.  Unlike  MS,  there  is  no  effective
harmacological  therapy  for  AS.  Pulmonary  congestion  can
e  relieved  with  diuretics,  although  these  should  be  avoided
s  much  as  possible  due  to  the  risk  of  hypotension  and
educed  placental  blood  ﬂow.  Where  there  are  signs  and
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ymptoms  of  HF,  syncope  or  angina,  percutaneous  or  surgical
ntervention  is  indicated.23
ortic  regurgitation
ike  AS,  the  most  common  cause  of  AR  in  young  women  is
icuspid  aortic  valve.  Women  with  severe  AR  and  preserved
ystolic  function  usually  tolerate  pregnancy  well.  However,
evere  AR  associated  with  LVD  due  to  increased  CO  and
lasma  volume  is  poorly  tolerated.  Symptomatic  pregnant
omen  should  receive  HF  therapy.22
ulmonary  stenosis
solated  pulmonary  stenosis  is  more  common  when  there
re  congenital  abnormalities  of  the  pulmonary  valve.
ven  in  women  with  severe  pulmonary  stenosis,  cardiac
omplications  (HF  and  low  CO)  during  pregnancy  are
are,  but  if  present  they  can  be  treated  by  percutaneous
alvuloplasty,  with  good  results  at  any  gestational  age.26
on-cardiac  complications  have  been  reported,  including
ypertensive  disorders,  prematurity  and  thromboembolic
omplications.27
ricuspid  regurgitation
he  causes  of  primary,  non-trivial,  TR  in  young  women
nclude  CHD  (for  example  Ebstein’s  anomaly,  which,  depend-
ng  on  its  complexity,  can  affect  the  prognosis),  rheumatic
alve  disease,  and  infective  endocarditis.  TR  is  usually  well
olerated  during  pregnancy.  However,  in  surgically  corrected
r  uncorrected  CHD  in  which  the  tricuspid  is  the  only  atrio-
entricular  valve,  the  valve  becomes  regurgitant  and  may
e  associated  with  ventricular  dilatation  and  dysfunction,
hich  increases  the  pregnancy  risk.28
rosthetic  valves
hen  a  woman  who  may  become  pregnant  has  a native
alve  replaced,  the  risks  and  beneﬁts  of  a  biological  valve
risk  of  structural  deterioration  and  less  durability,  with  90%
ikelihood  of  reintervention  for  valve  replacement  after  15
ears,29 but  with  no  need  for  anticoagulation)  need  to  be
eighed  against  those  of  a  mechanical  valve  (greater  dura-
ility  and  better  hemodynamic  proﬁle,  but  higher  risk  of
hromboembolism  and  consequent  need  for  lifelong  anti-
oagulation).  Pregnancy  is  usually  well  tolerated  in  women
ith  biological  valves;  maternal  cardiovascular  risk  depends
n  valve  and  ventricular  function  to  a  similar  extent  to
ative  valve  disease.  Monitoring  of  the  pregnancy  is  similar
o  that  for  native  valve  disease.  The  risk  of  valve  thrombosis,
leeding  and  fetal  complications  is  higher  with  mechanical
alves.
A retrospective  study  published  in  2015  of  84  pregnant
omen  with  valve  disease  (23  of  whom  had  prosthetic
alves)  demonstrated  that  pregnancy  in  women  with  pros-
hetic  valves  was  associated  with  high  maternal  and  fetal
orbidity.30 2015  also  saw  publication  of  data  on  the
utcomes  of  pregnancy  in  women  with  prosthetic  valves
rom  the  ESC’s  Registry  Of  Pregnancy  And  Cardiac  Disease
a
a
tT.  Guimarães  et  al.
ROPAC).31 This  registry  included  212  patients  with  mechan-
cal  valves,  134  with  biological  valves  and  2620  without  a
rosthetic  valve.  Maternal  mortality  was  1.5%  in  the  group
ith  prosthetic  valves  and  0.2%  in  women  without  (p=0.025).
alve  thrombosis  occurred  in  10  women  with  mechanical
alves,  and  bleeding  complications  were  also  more  common
n  this  group  (23%  vs.  5%  both  in  women  with  biological  valves
nd  in  those  without  a  prosthetic  valve,  p<0.001).  Event-
ree  survival  was  78%  in  women  without  prosthetic  valves,
9%  in  those  with  biological  valves  and  only  58%  in  those  with
echanical  valves  (p=0.001).  Furthermore,  fetal  outcomes
f  mothers  with  mechanical  valves  was  worse,  with  signif-
cantly  higher  incidences  of  miscarriage,  death  and  lower
irthweight.  Many  specialists  therefore  prefer  to  replace  the
ative  valve  with  a  biological  valve  in  women  who  wish  to
ecome  pregnant,  not  only  because  of  the  lower  associated
isk,  but  also  because  studies  have  demonstrated  that  preg-
ancy  does  not  affect  degeneration  of  biological  valves,32
nd  because  they  permit  percutaneous  valve-in-valve  treat-
ent,  which  is  likely  to  be  required  for  intermediate-  and
igh-risk  patients  in  the  future.
nticoagulation
regnancy  is  a  prothrombotic  state,  due  not  only  to  the
enous  stasis  with  which  it  is  associated,  but  also  to  hyperco-
gulability  resulting  from  increasing  levels  of  thrombogenic
actors  throughout  pregnancy.33 However,  the  maternal  and
etal  complications  associated  with  different  anticoagula-
ion  regimens,  and  the  lack  of  randomized  clinical  trials  and
onsistent  guidelines,  mean  that  management  of  anticoag-
lation  during  pregnancy  is  problematic.22
Warfarin,  a  vitamin  K  antagonist,  crosses  the  placenta,
nd  its  use  in  the  ﬁrst  6-12  weeks  of  pregnancy  is  associated
ith  fetal  complications,  including  warfarin  embryopathy
1-30%)  and  miscarriage  (15-56%),22 and  a  higher  incidence
f  miscarriage  and  fetal  intracranial  bleeding  throughout
regnancy,30 the  incidence  of  which  varies  in  different
tudies.34,35 However,  when  maintained  throughout  preg-
ancy,  it  offers  the  best  thromboembolic  protection  in
omen  with  mechanical  valves.  Although  they  included  few
atients,  studies  have  shown  that  the  risk  of  fetal  toxicity
s  lower  when  therapeutic  anticoagulation  is  achieved  with
arfarin  doses  ≤5  mg/day  rather  than  with  higher  doses.36,37
n  the  basis  of  these  ﬁndings,  the  ESC  and  ACC/AHA  con-
ider  vitamin  K  antagonists  safe,  recommending  warfarin  <5
g/day  (or  phenprocoumon  <3  mg/day  or  acenocoumarol
2  mg/day)  throughout  pregnancy  (ESC:  class  IIa  recom-
endation,  level  of  evidence  C;  AHA/ACC:  class  IIa,  level
).14,38 When  the  dose  needed  to  achieve  the  target  INR
s  higher  than  those  above,  vitamin  K  antagonists  should
e  replaced  by  continuous  low  molecular  weight  heparin
LMWH)  or  unfractionated  heparin  (UFH)  during  the  ﬁrst
rimester,  the  critical  stage  of  organogenesis.  However,  this
pproach  is  debatable,  because  other  studies  have  demon-
trated  that  warfarin  is  associated  with  fetal  mortality  even
t  low  doses.39
The  AHA/ACC  recommend  aspirin  75-100  mg/day  in
ssociation  with  warfarin  during  the  second  and  third
rimesters.38
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UFH  does  not  cross  the  placenta  and  thus  has  no
direct  effect  on  the  fetus.  Subcutaneous  administration
is  not  effective,  and  is  not  therefore  recommended  due
to  the  risk  of  thromboembolic  complications,40 but  intra-
venous  UFH  is  the  most  appropriate  form  of  anticoagulation
pre-  and  post-birth  due  to  its  rapid  onset  of  action  and
elimination.
Like  UFH,  LMWH  does  not  cross  the  placenta,  but  has
a  better  safety  proﬁle  (greater  bioavailability  and  longer
half-life,  and  lower  risk  of  bleeding  and  of  heparin-induced
thrombocytopenia).40 However,  its  efﬁcacy  during  preg-
nancy  is  debatable.  Some  studies  have  shown  similar  efﬁcacy
to  that  of  warfarin  in  women  with  mechanical  valves  if
administered  at  the  correct  dosage  (twice  daily  based  on
the  mother’s  body  weight)  and  with  anti-Xa  levels  measured
4-6  hours  after  administration,  for  a  target  value  of  0.8-1.2
U/ml.35 However,  a  study  of  15  pregnant  women  receiv-
ing  full-dose  LMWH  (1  mg/kg±20%  subcutaneously  twice
daily)  showed  that  factor  anti-Xa  levels  were  subtherapeu-
tic  in  over  50%  of  cases  and  that  levels  varied  considerably
between  administrations.41
Warfarin  should  be  suspended  at  least  a  week  before
delivery,  in  a  hospital  environment,  and  should  be  switched
to  LMWH  or  UFH.  If  warfarin  is  replaced  by  LMWH,  the
latter  should  be  suspended  36  hours  before  delivery  and
UFH  started.  In  turn,  UFH  should  only  be  suspended  4-6
hours  before  the  birth  and  resumed  6-8  hours  afterwards  if
hemostasis  is  ensured.  The  management  of  warfarin  therapy
varies  between  centers  but  it  should  be  resumed  48  hours
after  childbirth.
Use  of  the  new  oral  anticoagulants  is  increasing  in  non-
pregnant  women.  The  US  Food  and  Drug  Administration
recently  gave  rivaroxaban  a  class  C  recommendation  in
pregnancy,  but  there  have  as  yet  been  no  reports  on  its
use.42
Complex  congenital  heart  disease
CHD  accounts  for  80%  of  heart  disease  in  pregnant  women
in  the  Western  world.43 Some  categories  of  CHD,  such  as
Fontan  circulation,  systemic  right  ventricle  and  uncorrected
cyanotic  CHD,  are  associated  with  high  maternal  and  fetal
risk.  In  patients  with  Fontan  circulation,  10%  of  pregnan-
cies  are  associated  with  maternal  complications,  the  most
common  of  which  are  arrhythmias,  and  there  may  also
be  thromboembolic  complications  and  worsening  of  HF.44,45
There  is  agreement  that  Fontan  patients  with  impaired
ventricular  function,  severe  atrioventricular  regurgitation
and  enteropathy  should  be  counseled  against  pregnancy.14
Women  with  a  systemic  right  ventricle  (following  Mustard
or  Senning  surgery  or  with  congenitally  corrected  transpo-
sition  of  the  great  vessels)  have  a  similar  risk  of  cardiac
complications  (10-30%),  and  should  be  assessed  before  preg-
nancy.  Pregnancy  should  be  discouraged  in  the  presence  of
severe  right  ventricular  dysfunction  or  TR.14 In  uncorrected
cyanotic  CHD  without  PH,  32%  of  pregnancies  are  associ-
ated  with  complications,  most  often  HF.  Fetal  outcome  is
directly  related  to  the  mother’s  oxygen  saturation  at  rest
(≤85%  saturation  is  associated  with  fetal  survival  of  only
12%).46
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ulmonary  hypertension
H  is  associated  with  high  maternal  mortality,  but  advances
n  pulmonary  vasodilator  therapy  have  raised  hopes  of
mprovements  in  prognosis.47 Among  types  of  PH,  the
est  prognosis  is  seen  with  idiopathic  PH  under  speciﬁc
herapy,  for  which  mortality  is  9%.48 In  this  group,  women
ith  vasoreactive  PH  who  are  stable  under  calcium  chan-
el  blocker  therapy  have  a  relatively  good  prognosis  during
regnancy.49
Despite  improvements  in  prognosis  for  women  with  PH  in
ecent  decades,  this  condition  is  still  associated  with  high
ortality,  and  is  categorized  as  risk  level  IV  in  the  WHO
lassiﬁcation.  No  criteria  have  been  agreed  for  identifying
omen  with  lower  risk  during  pregnancy,  and  all  women
iagnosed  with  PH  are  advised  not  to  become  pregnant.14 If
 woman  decides  to  continue  with  the  pregnancy,  she  should
e  referred  to  a  center  specializing  in  PH  and  followed
y  a  multidisciplinary  team.  Pulmonary  vasodilator  therapy
n  use  before  pregnancy  should  be  continued,  except  for
ndothelin  receptor  antagonists  (bosentan,  macitentan  and
mbrisentan),  which  are  teratogenic  and  should  be  replaced
y  sildenaﬁl  and/or  prostacyclin  derivatives.
eripartum  cardiomyopathy
n  2010,  the  ESC’s  working  group  on  PPCM  proposed  a  simpli-
ed  deﬁnition  of  this  entity,  as  an  idiopathic  cardiomyopathy
requently  manifested  by  HF  secondary  to  LV  systolic  dys-
unction  (LVEF  <45%)  towards  the  end  of  pregnancy  or  in
he  months  following  delivery,  where  no  other  cause  of  HF
s  found.50 As  there  is  as  yet  no  speciﬁc  examination  for
iagnosing  PPCM,  it  is  a  diagnosis  of  exclusion  and  must
e  differentiated  from  existing  heart  failure  decompen-
ated  by  the  hemodynamic  changes  underlying  pregnancy.
hat  little  epidemiological  information  is  available  on  this
ntity  comes  mainly  from  Nigeria,  South  Africa  and  Haiti,
here  its  incidence  is  higher,  and  the  US,  where  its  inci-
ence  is  increasing.51 In  2017,  Sliwa  et  al.  published  data
athered  between  2012  and  2016  in  the  EURObservational
esearch  Programme52 demonstrating  that  PPCM  occurs  in
omen  from  all  over  the  world,  with  different  ethnic
rigins  and  socioeconomic  conditions,  but  with  very  sim-
lar  forms  of  presentation  and  course.  Risk  factors  that
ave  been  identiﬁed  are  African-American  descent,  older
aternal  age,  multifetal  pregnancies  and  hypertensive  dis-
rders  during  pregnancy.51 Although  its  etiology  remains
nknown,  various  mechanisms  have  been  suggested,  such  as
ow  selenium  levels,  reactivation  of  latent  viral  infections,
tress-activated  cytokines,  inﬂammation,  autoimmune  reac-
ions,  pathological  response  to  hemodynamic  stress  and
nbalanced  oxidative  stress.53 Recently  a  new  potentially
ausal  factor  has  been  described,  cleavage  of  prolactin
o  produce  a  16-kDa  N-terminal  prolactin  fragment  (16K
RL),  mediated  by  oxidative  stress.54 The  antiangiogenic
ffect  of  16K  PRL  and  of  soluble  fms-like  tyrosine  kinase-
 (sFlt-1),  levels  of  which  are  also  high  in  this  condition,
an  change  the  balance  of  angiogenesis,  leading  to  vascu-
ar  damage  and  hence  HF.53 The  high  incidence  of  PPCM
n  Africans  and  a  family  history  in  16%  of  cases  have
uggested  a possible  genetic  cause,55 but  the  mutations
380  T.  Guimarães  et  al.
Initial assessment
PPCM without hemodynamic instabilityProbable PPCM with hemodynamic instability
Hemodynamic assessment Diagnosis
12-lead ECG
Blood tests including natriuretic peptides
Echocardiography, lung ultrasound
Additional tests to exclude differential diagnoses
SBP <90 mmHg; HR >130 bpm or <45 bpm
RR >25/min; SpO2 <90%
Blood lactate >2.0 mmol/l; ScvO2 <60%
Altered mental state; cold skin; oliguria (<0.5 ml/kg/min)
Optimize preload
Volume vs. diuretics; vasodilators if SBP >110 mmHg
Optimize oxygenation
Consider non-invasive vs. invasive ventilation (if change in
consciousness or persistent hypoxemia)
Add inotropes and/or vasopressors
Consider levosimendan 0.1 µ/kg/min for 24 hours
Urgent delivery (cesarean section)
Consider bromocriptine (2.5 mg twice daily)
Consider mechanical circulatory support
if refractory cardiopulmonary distress
Recovery?
No
Heart transplantation
Yes
Weaning
Continue HF therapy
(for ≥12 months after recovery of LV function)
Consider wearable cardioverter-defibrillator
if LVEF ≤35%
Consider delivery
HF therapy
Hydralazine
Nitrates
BB (metoprolol)
Diuretics (if volume
overload)
HF therapy
ACEIs (or ARBs)
BBs
Spironolactone
Diuretics
Ivabradine
Consider bromocriptine
(2.5 mg twice daily)
Antepartum Postpartum
Figure  1  Algorithm  for  management  of  patients  with  peripartum  cardiomyopathy  (adapted  from  Bauersachs  et  al.12).  ACEIs:
angiotensin-converting  enzyme  inhibitors;  ARBs:  angiotensin  receptor  blockers;  BBs:  beta-blockers;  ECG:  electrocardiogram;  HF:
heart failure;  HR:  heart  rate;  IV:  invasive  ventilation;  LV:  left  ventricular;  LVEF:  left  ventricular  ejection  fraction;  PPCM:  peripartum
cardiomyopathy;  RR:  respiratory  rate;  SBP:  systolic  blood  pressure;  SpO2:  peripheral  oxygen  saturation;  SvcO2:  central  venous
oxygen saturation.
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pocumented  so  far  are  associated  with  familial  forms  of
ardiomyopathy.
The  majority  of  patients  admitted  with  PPCM  have  typical
ymptoms  and  signs  of  HF.  Differential  diagnosis  should  be
ade  with  other  entities  including  myocarditis,  pre-existing
ardiomyopathy,  valve  disease  and  congenital  heart  disease.
hen  presentation  is  with  cardiogenic  shock,  myocardial
nfarction  and  pulmonary  embolism  should  immediately  be
xcluded.12 An  ECG  should  be  performed  in  all  patients
uspected  of  having  PPCM,  even  though  there  is  no  spe-
iﬁc  electrocardiographic  pattern,  due  to  its  high  negative
redictive  value.  N-terminal  pro-B-type  natriuretic  pep-
ide  (NT-proBNP)  levels  are  usually  high  and  can  be  used
o  exclude  non-cardiac-related  dyspnea,  although  it  does
ot  help  differentiate  PPCM  from  other  cardiomyopathies.
TE  should  be  performed  as  soon  as  possible  in  all  cases
f  suspected  PPCM,  to  exclude  other  heart  disease  and
w
i
vomplications  such  as  apical  thrombus,  and  to  obtain  prog-
ostic  information.  Although  prognosis  is  more  favorable  in
PCM  than  in  other  cardiomyopathies,  it  is  associated  with
igniﬁcant  mortality  (<5-50%)  and  morbidity  (PE,  cardiogenic
hock,  arrhythmias  and  thromboembolic  events).12 Mortal-
ty  risk  is  higher  with  advanced  maternal  age,  multiparity,
everely  impaired  global  systolic  function,  African-American
ace  and  late  diagnosis.4 The  proportion  of  patients  who
ecover  left  ventricular  function  (LVEF  ≥50%)  varies  accord-
ng  to  the  study  (35-70%),  but  in  most  cases  this  occurs
ithin  six  months  of  childbirth.51 Recent  studies  show  that
frican-American  race  and  lower  LVEF  and  greater  LV  end-
iastolic  volume  at  diagnosis  are  associated  with  a  lower
robability  of  recovery.56 In  subsequent  pregnancies,  women
ith  persistent  LVD  are  at  greater  risk  (around  50%)  of  clin-
cal  deterioration  than  those  with  complete  recovery  of
entricular  function,  although  in  the  latter  there  may  be
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recurrence  in  another  pregnancy  (cardiac  function  worsens
in  around  20%,  in  20-50%  of  whom  this  persists  following
delivery).57
From  a  therapeutic  standpoint,  the  approach  to  PPCM  is
similar  to  that  of  other  causes  of  acute  HF,  taking  care  to
avoid  adverse  effects  on  the  fetus.  Figure  1  shows  a  proposed
treatment  algorithm,  according  to  the  patient’s  hemody-
namic  stability.  In  hemodynamically  unstable  patients  a
rapid  and  systematic  approach  is  essential  in  order  to
provide  support  and  prevent  target  organ  damage.  This
is  one  of  the  few  situations  in  which  an  emergency
cesarean  section  is  indicated  to  treat  the  mother,  with
the  aim  of  starting  bromocriptine.58 Regarding  inotropic
support,  levosimendan  is  preferred  in  these  patients  as
it  does  not  increase  myocardial  oxygen  consumption,
while  catecholamines  should  be  avoided.  If  levosimen-
dan  is  unavailable,  dobutamine  is  the  inotrope  of  choice,
and  noradrenaline  should  be  used  as  a  vasopressor
agent.12 Angiotensin-converting  enzyme  inhibitors  (ACEIs),
angiotensin  receptor  blockers  and  renin  inhibitors  are  con-
traindicated  during  pregnancy  due  to  their  fetal  toxicity.
Alternatively,  nitrates  and  hydralazine  can  be  used  to  reduce
pre-  and  afterload,  respectively.  After  childbirth,  ACEIs
can  be  resumed,  preferably  captopril  and  enalapril  dur-
ing  breastfeeding.  While  beta-blockers  increase  the  risk  of
intrauterine  growth  restriction,  they  can  be  used  in  hemo-
dynamically  stable  patients,  preferably  beta  1  selective
beta-blockers  such  as  metoprolol  succinate.  Mineralocorti-
coid  receptor  antagonists  should  be  avoided  in  pregnancy
and  breastfeeding.14 Bromocriptine,  in  association  with  HF
therapy,  should  be  considered  in  view  of  its  promising
results  in  terms  of  recovery  of  LV  systolic  function  and  clin-
ical  improvement.59 In  a  German  retrospective  registry  of
PPCM,  treatment  with  beta-blockers,  ACEIs  and  bromocrip-
tine  (2.5  mg  twice  daily  for  two  weeks  followed  by  2.5
mg  once  daily  for  six  weeks)  was  associated  with  favorable
outcomes.60 Anticoagulation  with  heparin  should  be  started
in  patients  with  PPCM  under  bromocriptine  and/or  with  LVEF
≤35%  (during  pregnancy  and  for  at  least  eight  weeks  after
delivery).61,62 Treatment  to  counteract  ventricular  remodel-
ing  should  be  continued  for  at  least  12  months  after  recovery
of  LV  dimensions  and  function.  Although  the  main  cause  of
death  in  PPCM  is  HF,  one  quarter  of  deaths  occur  due  to
ventricular  arrhythmias,  most  in  the  ﬁrst  six  months.63 The
use  of  wearable  cardioverter-deﬁbrillators  for  six  months
after  diagnosis  of  PPCM  has  been  proposed  for  women  with
severe  LV  dysfunction,  as  a  bridge  to  recovery  of  LV  function
or  placement  of  an  implantable  cardioverter-deﬁbrillator.63
Conclusions
The  association  between  heart  disease  and  pregnancy  is
increasingly  prevalent.  Pregnancy  involves  various  adap-
tations  which  are  not  always  tolerated  by  patients  with
existing  heart  disease.  Assessment  and  monitoring  of  women
with  known  or  suspected  heart  disease  who  wish  to  become
pregnant  should  therefore  begin  before  pregnancy  so  that
the  individual’s  risk  can  be  stratiﬁed  and  the  measures  to  be
taken  can  be  scheduled  in  advance.  Detection  of  a  devel-
oping  cardiovascular  disorder  must  also  be  a  priority  in
the  monitoring  of  the  pregnancy  and  if  one  is  identiﬁed,
1381
he  cardiology  team  should  immediately  be  involved.  It  is
ncreasingly  common  to  have  teams  dedicated  to  dealing
ith  cardiac  disorders  in  pregnancy,  an  approach  that  is
ecommended,  since  it  leads  to  better  clinical  outcomes.
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